Mountain Sickness
7
0
1
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
14%
1 trials in Phase 3/4
60%
3 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (7)
The Psychophysiological Effect of Simulated and Terrestrial Altitude
Pharmacologic Induction of Tolerance for Hypoxia & Hypothermia
Three New Ideas to Protect Special Forces From the Stress of High Altitude
Chronic Mountain Sickness, Systemic Vascular Function
Safety Evaluation of Aminophylline and Methazolamide
Study of Cobalt's Role in Excessive Erythrocytosis Among High Altitude Dwellers in Cerro de Pasco, Peru
Study of the Effects of Iron Levels on the Lungs at High Altitude